

ACMD

Advisory Council on the Misuse of Drugs

Chair: Dr Owen Bowden-Jones
Secretary: Zahi Sulaiman
1st Floor (NE), Peel Building
2 Marsham Street
London
SW1P 4DF
Tel: 020 7035 1121
ACMD@homeoffice.gsi.gov.uk

Sarah Newton MP
Minister for Vulnerability, Safeguarding and Countering Extremism
Home Office
2 Marsham Street
London
SW1P 4DF

23 March 2017

Dear Minister,

RE: Advice on scheduling for methylphenidate-related NPS

Thank you for your letter, dated 16 March 2017, accepting the ACMD's recommendation to control 12 methylphenidate-related Novel Psychoactive Substances in Class B of the Misuse of Drugs Act 1971.

Having consulted with our stakeholders to determine whether there are legitimate uses of these substances, the ACMD are now in a position to provide further advice in relation to their scheduling (please see Annex A for details of the organisations consulted).

Based on the feedback from the consultation, the ACMD is not aware of any confirmed legitimate medicinal, industrial or commercial uses of these substances. The ACMD therefore recommends that **ethylphenidate** and the following closely-related materials be placed in **Schedule 1** of the Misuse of Drugs Regulations 2001 (as amended):

Methylnaphthidate ('HDMP-28')
Isopropylphenidate ('IPP' or 'IPPD')
Propylphenidate
4-Methylmethylphenidate
Ethylphenidate ('HDEP-28')
N-Benzyl-ethylphenidate
3,4-Dichloroethylphenidate

3,4-Dichloromethylphenidate ('3,4-DCMP')
Methylmorphenate
4-Fluoromethylphenidate
4-Fluoroethylphenidate

We would like to thank our stakeholders who responded to the consultation.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Owen Bowden-Jones". The signature is written in a cursive style with a long, sweeping tail on the final letter.

Dr Owen Bowden-Jones
(Chair of ACMD)

Annex A

Bodies contacted by the ACMD to check for legitimate uses (during consultation period 28 February – 15 March 2017)

- Medical Research Council (MRC)
- Department of Health
- Public Health England (PHE)
- Pistoia Alliance
- Office for Life Science (OLS)
- Department for Business, Energy and Industrial Strategy (BEIS)
- Medicines and Healthcare products Regulatory Agency (MHRA)
- The Academy of Medical Sciences (AMS)
- Association of the British Pharmaceutical Industry (ABPI)
- Health Research Authority (HRA)
- The Royal Society
- British Pharmacological Society (BPS)